NYSE:NKE

Nike (NYSE: NKE) Navigates Revenue Miss and Weak Outlook Amidst China Challenges

Font: Financial Modeling Prep  • Oct 01, 2026

Market Chart
  • Nike surpassed EPS estimates but reported a revenue miss for the quarter.
  • Weak demand in the crucial Greater China market and increased competition are impacting sales performance.
  • The global sportswear giant issued a weaker-than-expected fiscal 2027 earnings and revenue outlook, leading to a stock decline.

Nike (NYSE: NKE), a leading global sportswear brand, reported earnings of $0.48 per share, surpassing analysts’ estimate of $0.44. However, its revenue of $11.21 billion fell short of the $11.32 billion estimate. Nike, known for its athletic footwear, clothing, and equipment, demonstrated stronger-than-expected earnings per share despite the revenue miss, highlighting efficient cost management.

Weak consumer demand in China and an increasingly stronger competitive landscape continue to weigh on Nike's sales performance, as highlighted by Reuters. CEO Elliott Hill noted that Nike’s “Sport Offense” strategy is making measurable progress within its performance business segment. However, the company acknowledges significant work remains in key areas such as Sportswear, the Jordan Brand, and the crucial Greater China market.

Looking ahead, investors also face a weaker financial outlook. Nike forecasts fiscal 2027 adjusted earnings per share (EPS) to be between $1.15 and $1.35, significantly below analysts’ estimate of $1.65. The company also warned of a high-single-digit revenue decline for the year, as reported by Proactive Investors. Following this cautious guidance, Nike's shares experienced a notable drop of 5.8% in after-hours trading.

From a valuation perspective, Nike’s trailing price-to-earnings (P/E) ratio stands at 16.8, indicating its share price is 16.8 times its earnings per share over the past year. Its price-to-sales (P/S) ratio is 1.13. Assessing the company’s financial health, the debt-to-equity ratio is 0.29, while its current ratio of 2.07 demonstrates its ability to cover short-term liabilities with assets convertible to cash within a year.

Market Overview
NIVF
NewGenIvf Group Limited
$0.13
27.72%
FNGR
FingerMotion, Inc.
$0.25
41.15%
AMOD
Alpha Modus Holdings, Inc.
$3.49
198.29%
FLUX
Flux Power Holdings, Inc.
$0.64
57.40%
SCNX
Scienture Holdings, Inc.
$0.16
-10.33%
SDEV
NovaBay Pharmaceuticals, Inc.
$7.48
104.37%
NKE
NIKE, Inc.
$33.87
-3.64%
NVDA
NVIDIA Corporation
$233.95
1.34%
QTEX
QTREX Quantum Ltd.
$1.10
40.20%
SPCX
Space Exploration Technologies Corp.
$158.96
7.35%